\
&
Contact us
\
&
Contact us
Published on | 3 years ago
ProgrammesThe European Commission has published the first calls under the 2023 Digital Europe work programme. The calls cover a broad range of topics under the special objectives AI, Data & Cloud, Advanced Digital Skills and Deployment: Accelerating Best Use of Technologies.
The calls will be open for submission of proposals as of 11 May 2023, the deadline is 26 September 2023.
We strongly advise the registered users of our website to check your profile (and if needed, update them) to ensure that you have not only selected to be informed on general aspects of the programme, but that you also selected the Special Objectives that are of interest to you.
Information on specific call topics (such as changes to the call texts, specific info sessions etc.) will be published on the dedicated pages of the Specific Objectives, not on the general Digital Europe page. Please make sure that you do not miss any relevant information.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
